Relapse of morphea during Nivolumab therapy for lung adenocarcinoma.
Dermatology Service, Ramon y Cajal Hospital, Madrid, Spain. Electronic address: adrian.alegresanchez@gmail.com.
A
A
Alegre-Sánchez
Dermatology Service, Ramon y Cajal Hospital, Madrid, Spain.
P
P
Fonda-Pascual
Dermatology Service, Ramon y Cajal Hospital, Madrid, Spain.
D
D
Saceda-Corralo
Dermatology Service, Ramon y Cajal Hospital, Madrid, Spain.
E
E
de Las Heras-Alonso
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy*; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D012008:Recurrence; D016879:Salvage Therapy; D012594:Scleroderma, Localized / Q000139:chemically induced* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab